Author: Editor

John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai shares outcomes from the MANIFEST study investigating CPI-0610 as a monotherapy or add-on to ruxolitinib in patients with myelofibrosis.

Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine compares the effectiveness of rasburicase versus allopurinol in cancer patients with hyperuricemia.

Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine describes those patient types more suited for treatment with rasburicase versus allopurinol.

Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine discusses the advantages of rasburicase compared to allopurinol in managing tumor lysis syndrome (TLS) in patients with renal dysfunction.

Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine considers whether there are particular patient types more prone to tumor lysis syndrome (TLS).

Immunomedics has developed an antibody drug conjugate (ADC) called sacituzumab govitecan, which directly delivers chemotherapy SN-38 to triple negative breast cancer (TNBC) tumours, which highly express the glycoprotein Trop-2 and represents an unmet need within a highly treated cancer type. GlobalData’s pharmaceutical technology writer Allie Nawrat says: “The New Jersey-based firm has developed a novel ADC platform centred around its specialised hydrolysable linker, which delivers potent chemotherapy metabolites directly to cancer tumour sites and their microenvironments. “Immunomedics’ lead candidate, sacituzumab govitecan, is currently being developed for heavily treated TNBC patients. The company has received US Food and Drug Administration breakthrough…

Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC explains how JNJ-4528 differs from other CAR-T products.

Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC tells us about the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed refractory multiple myeloma.

Deepu Madduri, MD Assistant Professor, Medicine, Hematology and Medical Oncology, @MountSinaiNYC on how CAR-T cell therapy plays a role in the management of multiple myeloma.

Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL).

Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers whether minimal residual disease (MRD) is a valid endpoint when measuring the efficacy of treatment in chronic lymphocytic lymphoma (CLL).

Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA tells us about the four-year update on the outcomes of the MURANO study investigating venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic lymphoma.

Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers the ideal patient profile for zanubrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL).

Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, tells us about the data with CAR-T cell therapy outside of clinical trials.

Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, regarding the clinical evidence supporting CAR-T cell therapies in multiple myeloma.

Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, provides his impression of the Transcend-NHL study investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL).

Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, offers opinion regarding off-the-shelf CAR-T cell therapies.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, provides insight on the real-world evidence presented at ASH 2019 regarding CAR-T cell therapy in lymphoma.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, offers perspective on the role of umbralisib in the management of relapsed/refractory lymphoma.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, discusses how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia.

Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, offers her perspective on the latest treatment trends in Burkitt lymphoma and other aggressive lymphomas.

Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the Phase 3 Dreamm-3 study, investigating belantamab versus pomalidomide and dexamethasone.

Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope describes the results of the Phase 1 study investigating CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in patients with relapsed/refractory multiple myeloma.

Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope tells us about the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma.

Amrita Krishnan, MD Professor, Department of Hematology and Hematopoietic Cell Transplantation, @cityofhope elaborates on BCMA-directed strategies for multiple myeloma patients.

GRACE is very excited to bring to you more videos from our program, Supportive Care in Cancer Treatment.Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video Dr. Gupta speaks with Christi M. Walsh, MSN, CRNP, with Johns Hopkins University in Baltimore, MD. Christi Walsh and Dr. Gupta discuss Pancreatic Enzyme Replacement Therapy, or PERT.To donate to CancerGRACE, visit https://cancergrace.org/donate.For more, please visit http://cancerGRACE.org/.To join the conversation, visit https://cancergrace.org/forum.

Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video Dr. Gupta speaks with Shaalan Beg, MD, with UT Southwestern Medical Center in Dallas, TX . Dr. Beg and Dr. Gupta discuss Malignant Ascites, or fluid in the belly, in patients with cancer.To donate to CancerGRACE, visit https://cancergrace.org/donate.For more, please visit http://cancerGRACE.org/.To join the conversation, visit https://cancergrace.org/forum.

Source: https://www.spreaker.com/user/cancergrace/supportive-care-5-chemobrain-podcast We are very excited to bring to you this new program on supportive care in cancer treatment. In this video, our host Dr. Arjun Gupta speaks with his guest, Lysa Buonanno, who is a lung cancer patient and patient advocate. Lysa and Dr. Gupta discuss the often poorly understood subject of ‘chemobrain’, or attention, thinking or memory problems in patients with cancer. For more information on Chemobrain, please visit https://www.cancer.net/sites/cancer.net/files/asco_answers_chemobrain.pdf To join the conversation, visit https://cancergrace.org/forum. To find additional CancerGRACE resources, visit https://cancergrace.org. To donate to CancerGRACE, visit https://cancergrace.org/donate.

Source: https://www.spreaker.com/user/cancergrace/supportive-care-6-pert Arjun Gupta, MD is the host of this video series, Supportive Care in Cancer Treatment. In this video, Dr. Gupta speaks with Christi M. Walsh, MSN, CRNP, with Johns Hopkins University in Baltimore, MD. Christi Walsh and Dr. Gupta discuss Pancreatic Enzyme Replacement Therapy, or PERT.

Michael Jain, MD Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews offers his opinion on off-the-shelf CAR-T cell therapy.

Michael Jain, MD Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews tells us about the outcomes of the US CAR-T Cell Consortium study investigating bridging therapy prior to delivery of CAR-T cell therapy.

Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews tells us about the outcomes of the US CAR-T Cell Consortium study investigating bridging therapy prior to delivery of CAR-T cell therapy.

Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews discusses how population-based outcomes in B-cell lymphomas are changing.

Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews offers perspective on the latest treatment trends for aggressive lymphomas.

Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM shares the the primary and secondary endpoints of the ECHELON-2 study.

Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM explains the purpose of targeting peripheral t-cell lymphoma (PTCL).

Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM describes the ECHELON-2 data presented at ASH 2019.

Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, offers insight of the Phase 3 ICARIA-MM trial investigating isatuximab in relapsed/refractory multiple myeloma.

Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, tells us about the design and outcomes of the STORM and Mammoth studies, investigating refractory multiple myeloma (MM) patients treated with selinexor plus dexamethasone or conventional care.

Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, explains how novel combination treatment options and sequencing strategies are used to manage relapsed/refractory multiple myeloma.

Parameswaran Hari, MD Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, elaborates on the role of stem cell transplantation in the treatment of multiple myeloma.

Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC considers whether off-the-shelf CAR-T cell therapies are becoming a reality.

Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC offers impressions of the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL).

Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC discusses the three-year survival analysis of the ZUMA-1 study investigating axicabtagene ciloleucel in diffuse large b-cell lymphoma (DLBCL) presented at ASH 2019.

Andre Goy, MD, Chairman, John Theurer Cancer Center, Part of @HackensackUMC tells us about the results of the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy in mantle cell lymphoma (MCL) patients.

Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth explains how oncologists are using RWE today.

Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth provides examples of how real-world evidence (RWE) has impacted decision-making in oncology.

Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, @cardinalhealth defines real-world evidence (RWE) and explains how it can be used to aid physicians.

James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses the future of off-the-shelf CAR-T cell therapy.